Src-Family B Kinase Inhibition Promotes Lung Endothelial Dysfunction and Guides Drug Discovery

Protein tyrosine kinase (PTK) inhibition is efficacious in treating conditions ranging from cancer to fibrosis but can be limited by endothelial cell dysfunction. In trials of protein tyrosine kinase inhibitors (TKIs) a broad range of vascular effects is observed, inducing clinically detrimental endothelial cell apoptosis, impaired barrier function, or improved pulmonary vascular resistance in pulmonary arterial hypertension (PAH). We hypothesize this range of effects is due to subsets of PTKs either impairing or promoting endothelial homeostasis by modulating Bone Morphogenetic Protein receptor 2 (BMPR2) signaling, a pathway essential for vascular development and dysfunctional in PAH. In a high-throughput siRNA screen we find SRC-Family B PTKs activate whereas SRC-Family A PTKs suppress BMPR2 signaling, measured by the transcription factor inhibitor of differentiation 1 (Id1). Induced loss of function of the strongest ID1 activating PTK LCK (a Src-B kinase) in human pulmonary artery endothelial cells suppresses BMPR2 signaling and induces multiple measures of endothelial dysfunction. However, loss of function of the strongest ID1 inhibitor PTK FYN (a Src- A kinase) does the opposite. Whole-genome transcriptional analysis identifies two multi-gene signatures inversely regulated by LCK and FYN we term “endothelial” and “inflammatory”. To find TKIs mimicking selective Src-A and Src-B inhibition, we use Connectivity map to identify drugs connecting to the endothelial and inflammatory signatures. We find several TKIs: a pro-inflammatory (Regorafanib), a BMPR2 potentiating (Brivanib), and a BMPR2 suppressing (Quizartinib). Here we show a dichotomy in pathway regulation by Src- A and -B kinases that may have utility in transcriptionally based drug discovery.

[1]  Purvesh Khatri,et al.  Computational drug repositioning of atorvastatin for ulcerative colitis , 2021, J. Am. Medical Informatics Assoc..

[2]  P. Khatri,et al.  iPSC–endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension , 2021, Science Translational Medicine.

[3]  W. Rasband,et al.  Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay” , 2020, Scientific Reports.

[4]  Irving L. Weissman,et al.  A molecular cell atlas of the human lung from single cell RNA sequencing , 2019, Nature.

[5]  M. Humbert,et al.  Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study , 2019, European Respiratory Journal.

[6]  Juan Antonio Vizcaíno,et al.  The functional landscape of the human phosphoproteome , 2019, Nature Biotechnology.

[7]  M. Pasmanik-Chor,et al.  Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells , 2019, Leukemia & lymphoma.

[8]  Delphine De Sutter,et al.  A protein-protein interaction map of the TNF-induced NF-κB signal transduction pathway , 2018, Scientific Data.

[9]  Christoph Hafemeister,et al.  Comprehensive integration of single cell data , 2018, bioRxiv.

[10]  A. Andruska,et al.  Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension , 2018, International journal of molecular sciences.

[11]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[12]  W. Chung,et al.  Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults , 2018, Circulation. Genomic and precision medicine.

[13]  Laura Scelsi,et al.  Functional analysis of a novel ENG variant in a patient with hereditary hemorrhagic telangiectasia (HHT) identifies a new Sp1 binding-site. , 2018, Gene.

[14]  Nathan C. Sheffield,et al.  BART: a transcription factor prediction tool with query gene sets or epigenomic profiles , 2018, bioRxiv.

[15]  J. Kuriyan,et al.  Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen , 2018, bioRxiv.

[16]  A. Weiss,et al.  TCR Signaling: Mechanisms of Initiation and Propagation. , 2017, Trends in biochemical sciences.

[17]  Hyojin Kim,et al.  TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions , 2017, Nucleic Acids Res..

[18]  Laleh Soltan Ghoraie,et al.  A review of connectivity map and computational approaches in pharmacogenomics , 2017, Briefings Bioinform..

[19]  M. Humbert,et al.  Dasatinib increases endothelial permeability leading to pleural effusion , 2017, European Respiratory Journal.

[20]  Stephanie L. K. Bowers,et al.  Src- and Fyn-dependent apical membrane trafficking events control endothelial lumen formation during vascular tube morphogenesis , 2017, PloS one.

[21]  H. Gerhardt,et al.  The endothelial transcription factor ERG mediates Angiopoietin-1-dependent control of Notch signalling and vascular stability , 2017, Nature Communications.

[22]  A. Looney,et al.  Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis , 2017, American journal of respiratory cell and molecular biology.

[23]  K. Vijayan,et al.  Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA‐ROCK pathway , 2017, Cancer medicine.

[24]  R. T. Bunch,et al.  In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension , 2017, Cancer Chemotherapy and Pharmacology.

[25]  Pin-i Chen,et al.  Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. , 2017, JCI insight.

[26]  G. Inman,et al.  TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling , 2017, Nature Communications.

[27]  K. McCrae,et al.  Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  George Papadatos,et al.  Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound–Kinase Activities: A Way toward Selective Promiscuity by Design? , 2016, J. Chem. Inf. Model..

[29]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[30]  P. Libby,et al.  Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis , 2016 .

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  Arup K Chakraborty,et al.  Insights into the initiation of TCR signaling , 2014, Nature Immunology.

[33]  M. D. de Caestecker,et al.  Abnormal Trafficking of Endogenously Expressed BMPR2 Mutant Allelic Products in Patients with Heritable Pulmonary Arterial Hypertension , 2013, PloS one.

[34]  George C Tseng,et al.  Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis , 2013, Science Translational Medicine.

[35]  D. Bernstein,et al.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. , 2013, The Journal of clinical investigation.

[36]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[37]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[38]  David J. Arenillas,et al.  oPOSSUM-3: Advanced Analysis of Regulatory Motif Over-Representation Across Genes or ChIP-Seq Datasets , 2012, G3: Genes | Genomes | Genetics.

[39]  B. Dahal,et al.  Integrative Physiology/experimental Medicine Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension Materials and Methods Mct Treatment, Inhibitor Treatment, and Hemodynamic Measurements Assessment of Vascular Remodeling and Proliferation in Situ Cell Culture Proliferation Assays Chemot , 2022 .

[40]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[41]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[42]  F. Giles,et al.  Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib , 2009, Drug design, development and therapy.

[43]  P. Zarrinkar,et al.  Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. , 2009, Journal of medicinal chemistry.

[44]  D. Rifkin,et al.  A rapid and sensitive bioassay to measure bone morphogenetic protein activity , 2007, BMC Cell Biology.

[45]  L. David,et al.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.

[46]  C. McMaster,et al.  TSAd interacts with Smad2 and Smad3. , 2006, Biochemical and biophysical research communications.

[47]  J. Fargnoli,et al.  Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. , 2006, Journal of medicinal chemistry.

[48]  C. Hirshman,et al.  Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[49]  T. Hunter,et al.  Vertebrate non‐receptor protein–tyrosine kinase families , 1996, Genes to cells : devoted to molecular & cellular mechanisms.